Skip to content
You are now leaving to visit

Phase 2 Results on AKCEA-APO(a)-LRx Presented in Late-Breaking Clinical Trial Presentation at AHA Scientific Sessions

Approximately 98% of patients receiving highest dose achieved reductions in Lp(a) levels below the established threshold of risk for CVD events Favorable safety and tolerability profile observed in largest study ever conducted in patients with cardiovascular disease and elevated Lp(a) BOSTON and